Lonza’s full-year core EBITDA up 20.7 per cent on vaccine demand
Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier
Swiss drug contract manufacturer Lonza said core earnings gained 20.7 per cent in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.
Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement yesterday.
- Advertisement -